Ozempic vs Wegovy: Understanding Semaglutide Options
Ozempic and Wegovy both contain semaglutide, but they are labeled for different FDA-approved uses. Patients often hear the names used interchangeably online, but that shortcut can create confusion around dosing, approval status, and insurance coverage.
Quick comparison table
| Category | Ozempic | Wegovy |
|---|---|---|
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA approval date | 2017 | June 2021; cardiovascular risk reduction indication added March 2024 |
| Approved indication | FDA-approved for type 2 diabetes, not weight loss, per FDA prescribing information. | FDA-approved for chronic weight management and later cardiovascular risk reduction, per FDA prescribing information. |
| Mechanism | GLP-1 receptor agonist per FDA prescribing information. | GLP-1 receptor agonist per FDA prescribing information. |
| Dosing frequency | Once weekly injection; starts at 0.25 mg and can escalate up to 2 mg weekly per FDA prescribing information. | Once weekly injection; starts at 0.25 mg and escalates monthly to 2.4 mg maintenance per FDA prescribing information. |
| Average weight loss | Semaglutide weight-loss trial data is usually associated with Wegovy studies, not an Ozempic weight-loss indication. | STEP 1 trial (NEJM 2021): average 14.9% body weight loss over 68 weeks with Wegovy; STEP 2 trial: 9.6% in adults with type 2 diabetes. |
| Common side effects | Nausea, diarrhea, vomiting, constipation, abdominal pain per semaglutide labeling. | Nausea, diarrhea, vomiting, constipation, abdominal pain per Wegovy prescribing information. |
| Approximate monthly cost range | About $900-1,000/month; prices vary by pharmacy and location as of early 2025. | About $1,300-1,400/month; prices vary by pharmacy and location as of early 2025. |
Drug facts on this page are summarized from FDA prescribing information and named clinical trials listed in the source notes below.
What is Ozempic?
Ozempic is Novo Nordisk's semaglutide product approved for type 2 diabetes, per FDA prescribing information. It is a once-weekly injectable GLP-1 receptor agonist. Because semaglutide became a highly visible drug category, many consumers now associate Ozempic with weight loss. The regulatory point to keep straight is that Ozempic itself is not FDA-approved for chronic weight management.
Per FDA prescribing information, Ozempic starts at 0.25 mg weekly, then usually increases to 0.5 mg, with up to 2 mg weekly depending on treatment needs. Common side effects listed for semaglutide include nausea, diarrhea, vomiting, constipation, and abdominal pain. Like other drugs in this category, Ozempic also carries a boxed warning about thyroid C-cell tumors observed in rodent studies and other important warnings that require medical review.
When clinics or patients cite dramatic semaglutide weight-loss numbers, it is important to verify whether those numbers come from Wegovy trials rather than Ozempic's diabetes label. Keeping the brand, indication, and trial context aligned helps avoid misleading claims.
What is Wegovy?
Wegovy is also semaglutide, but it is the brand approved for chronic weight management, per FDA prescribing information. It received FDA approval in June 2021 for adults with obesity or overweight plus a weight-related condition, and the reference file notes an added cardiovascular risk reduction indication in March 2024 following the SELECT trial.
The most commonly cited Wegovy outcome is the STEP 1 trial, published in NEJM in 2021, which reported average 14.9% body weight loss over 68 weeks versus 2.4% with placebo. STEP 2 reported 9.6% average weight loss in adults with type 2 diabetes, and STEP 3 reported 16% with intensive behavioral therapy. Those are average clinical-trial outcomes and should be described that way.
Per FDA prescribing information, Wegovy is titrated monthly from 0.25 mg up to a 2.4 mg maintenance dose. Its side effects overlap heavily with Ozempic because both contain semaglutide. In real-world comparisons, the biggest difference is usually not the molecule but the labeled indication, maintenance dose framework, insurance coverage, and the clinical problem being treated.
Key Differences
- Both contain semaglutide, per FDA prescribing information.
- Ozempic is FDA-approved for type 2 diabetes; Wegovy is FDA-approved for chronic weight management, per FDA prescribing information.
- Wegovy's most-cited trial result is STEP 1 at 14.9% average weight loss over 68 weeks, while Ozempic is not labeled for weight loss.
- Wegovy's maintenance dose reaches 2.4 mg weekly; Ozempic's label goes up to 2 mg weekly.
- Wegovy usually has a higher approximate retail price than Ozempic as of early 2025.
Which One Is Right for You?
This is not a recommendation. The better question is which factors you should discuss with your doctor before choosing a medication. Consult your healthcare provider about:
- Whether you need a diabetes medication, a weight-management medication, or both issues evaluated separately.
- How your insurer treats Ozempic compared with Wegovy.
- Whether the dosing goal and escalation plan fit your tolerance and medical history.
- How trial evidence such as STEP 1 and SELECT applies to your individual health profile.
- Whether side effects, boxed warnings, and other medications you use change the best discussion to have with your prescriber.
Side Effects Comparison
| Side effect or warning | Ozempic | Wegovy |
|---|---|---|
| Nausea | Common on semaglutide label | 44% (Wegovy label) |
| Diarrhea | Common on semaglutide label | 30% |
| Vomiting | Common on semaglutide label | 24% |
| Constipation | Common on semaglutide label | 24% |
| Abdominal pain | Common on semaglutide label | 20% |
| Boxed warning | Thyroid C-cell tumor warning in rodents | Thyroid C-cell tumor warning in rodents |
Side-effect summaries are based on FDA prescribing information. Individual experiences vary. Consult your healthcare provider.
Cost Comparison
Ozempic is approximately $900-1,000 per month without insurance as of early 2025.
Wegovy is approximately $1,300-1,400 per month without insurance as of early 2025.
Prices vary by pharmacy and location.
Coverage may differ based on whether the prescription is aligned with the FDA-approved indication and the payer's formulary rules.
Pricing is approximate and based on the reference file as of early 2025. Prices vary by pharmacy and location. Consult your healthcare provider and pharmacy for current pricing.
Frequently Asked Questions
Is Ozempic the same drug as Wegovy?
They contain the same active ingredient, semaglutide, but they have different FDA-approved indications and dosing context, per FDA prescribing information.
Which one is approved for weight loss?
Wegovy is FDA-approved for chronic weight management. Ozempic is FDA-approved for type 2 diabetes, per FDA prescribing information.
Why do people mention Ozempic for weight loss if Wegovy is the weight-loss brand?
The names are often discussed together because they share semaglutide, but the FDA-approved indication differs. Patients should discuss the appropriate product with their healthcare provider.
Do Ozempic and Wegovy have the same side effects?
Their side-effect profiles overlap substantially because both contain semaglutide, though clinicians still rely on the specific product labeling.
Did Wegovy show cardiovascular benefits?
Yes. The reference file notes the SELECT trial showed a 20% reduction in major cardiovascular events, which supported Wegovy's added cardiovascular indication in 2024.
Find Clinics
Browse GLP-1 clinics, compare treatment options, and bring these questions to a licensed medical professional. Consult your healthcare provider before starting any medication.
Find clinics offering semaglutide careData sources
- Ozempic prescribing information (FDA)
- Wegovy prescribing information (FDA)
- STEP 1 trial, NEJM 2021
- STEP 2 trial
- STEP 3 trial
- SELECT trial
Drug information sourced from FDA-approved prescribing labels and published clinical trial data. Pricing information is approximate and may not reflect current costs. Last updated March 2026.
This information is for educational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting any medication. Individual results may vary. Consult your healthcare provider.